Ricardo Sanchez Boix
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ricardo Sanchez Boix has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alexia Paganotti
Santa Casa de São Paulo School of Medical Sciences, São Paulo, SP, Brazil
3 shared publications - Felipe Menegueti
Irmandade Santa Casa de Misericórdia de São Paulo, Brasil
3 shared publications - Roberto Augusto Caffaro
Irmandade Santa Casa de Misericórdia de São Paulo, Brasil
3 shared publications - Eduardo Ramacciotti
Science Valley Research Institute, Brasil; Loyola University Medical Center, EUA
2 shared publications - Giuliano Giova Volpiani
Irmandade Santa Casa de Misericórdia de São Paulo, Brasil
2 shared publications - Samantha Neves
Irmandade Santa Casa de Misericórdia de São Paulo, Brasil
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 25, e20250065
Topical oxybutynin antiperspirant for axillary hyperhidrosis: a phase IIb PROBE design clinical trial (TODAY trial)
Background Primary hyperhidrosis is a chronic condition with limited therapeutic options. Objectives To evaluate the impact of 10% oxybutynin spray on axillary hyperhidrosis, considering both its local and systemic effects, in terms of Hyperhidrosis Disease Severity Scale (HDSS) outcomes for hyperhidrosis of the axilla and eight additional sites. Methods Prospective phase II PROBE design trial. Adult patients with axillary hyperhidrosis were randomized to receive a 10% oxybutynin topical spray, oral oxybutynin, or placebo spray for 35 days. Efficacy was evaluated on day 35 using the HDSS and a hyperhidrosis-specific quality-of-life (QoL) assessment questionnaire. Results 17 patients were randomized. No significant differences were observed in HDSS outcomes from baseline to day 35 in any of the three groups (2.5 [2 - 4], 4 [3 - 4], 3.5 [3 - 4], p= 0.207), although a trend to improvement was noted in both treatment groups. Significant improvement in the QoL questionnaire was observed from baseline to day 35 in the oxybutynin spray group (pre-intervention QoL: 78.5 [70 - 96] and post-intervention QoL: 38.5 [32 - 67], p = 0.031). Conclusions No differences were observed in the primary outcome. A significant improvement from baseline to day 35 was observed in the QoL questionnaire score for the oxybutynin spray group.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 25, e20250065
Open AccessTopical oxybutynin antiperspirant for axillary hyperhidrosis: a phase IIb PROBE design clinical trial (TODAY trial)
Background Primary hyperhidrosis is a chronic condition with limited therapeutic options. Objectives To evaluate the impact of 10% oxybutynin spray on axillary hyperhidrosis, considering both its local and systemic effects, in terms of Hyperhidrosis Disease Severity Scale (HDSS) outcomes for hyperhidrosis of the axilla and eight additional sites. Methods Prospective phase II PROBE design trial. Adult patients with axillary hyperhidrosis were randomized to receive a 10% oxybutynin topical spray, oral oxybutynin, or placebo spray for 35 days. Efficacy was evaluated on day 35 using the HDSS and a hyperhidrosis-specific quality-of-life (QoL) assessment questionnaire. Results 17 patients were randomized. No significant differences were observed in HDSS outcomes from baseline to day 35 in any of the three groups (2.5 [2 - 4], 4 [3 - 4], 3.5 [3 - 4], p= 0.207), although a trend to improvement was noted in both treatment groups. Significant improvement in the QoL questionnaire was observed from baseline to day 35 in the oxybutynin spray group (pre-intervention QoL: 78.5 [70 - 96] and post-intervention QoL: 38.5 [32 - 67], p = 0.031). Conclusions No differences were observed in the primary outcome. A significant improvement from baseline to day 35 was observed in the QoL questionnaire score for the oxybutynin spray group.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 24, e20240098
Topical oxybutynin deodorant for axillary hyperhidrosis: a topic or a systemic effect? Rationale and design of the phase II today trial
Anticholinergics have been shown to enhance quality of life and reduce sweat in patients with hyperhidrosis. However, it remains unclear whether topical application specifically exerts local or systemic effects. This study’s primary aim is to assess topical oxybutynin’s impact on axillary hyperhidrosis. Twenty patients will be randomized into three groups. Group A will receive 2.5 mg of oral oxybutynin from day 1 to day 35 (on a variable frequency regimen). Group B will be administered a topical placebo for 35 days and Group C will receive a 10% oxybutynin topical spray, to be used twice daily for 35 days. The primary efficacy outcome will be the evaluation of the effectiveness of topical oxybutynin spray in treating hyperhidrosis. The TODAY trial will generate high-quality evidence on the effects of topical oxybutynin, assessing whether its impact is local or systemic in patients with axillary hyperhidrosis.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 24, e20240098
Open AccessTopical oxybutynin deodorant for axillary hyperhidrosis: a topic or a systemic effect? Rationale and design of the phase II today trial
Anticholinergics have been shown to enhance quality of life and reduce sweat in patients with hyperhidrosis. However, it remains unclear whether topical application specifically exerts local or systemic effects. This study’s primary aim is to assess topical oxybutynin’s impact on axillary hyperhidrosis. Twenty patients will be randomized into three groups. Group A will receive 2.5 mg of oral oxybutynin from day 1 to day 35 (on a variable frequency regimen). Group B will be administered a topical placebo for 35 days and Group C will receive a 10% oxybutynin topical spray, to be used twice daily for 35 days. The primary efficacy outcome will be the evaluation of the effectiveness of topical oxybutynin spray in treating hyperhidrosis. The TODAY trial will generate high-quality evidence on the effects of topical oxybutynin, assessing whether its impact is local or systemic in patients with axillary hyperhidrosis.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 24, e20240098
Desodorante tópico de oxibutinina para hiperidrose axilar: efeito local ou sistêmico? Fundamentação e desenho do estudo de fase II today
Os anticolinérgicos melhoram a qualidade de vida com redução da sudorese em pacientes com hiperidrose, mas permanece incerto se a aplicação tópica exerce efeitos locais ou sistêmicos. O objetivo principal deste estudo é avaliar o impacto da oxibutinina tópica na hiperidrose axilar. Vinte pacientes com hiperidrose axilar serão randomizados em três grupos. O Grupo A receberá 2,5 mg de oxibutinina oral com diferentes posologias do primeiro ao 35º dia. O Grupo B receberá um placebo tópico na forma de spray, e o Grupo C receberá um spray de oxibutinina a 10%, com duas borrifadas em cada axila duas vezes ao dia por 35 dias (produto em investigação). O desfecho primário será a avaliação da eficácia do spray tópico de oxibutinina, avaliada pelo número de pacientes que apresentam melhora na gravidade da condição. O estudo TODAY mostrará evidências sobre os efeitos da oxibutinina tópica, avaliando seu impacto na hiperidrose axilar.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 24, e20240098
Open AccessDesodorante tópico de oxibutinina para hiperidrose axilar: efeito local ou sistêmico? Fundamentação e desenho do estudo de fase II today
Os anticolinérgicos melhoram a qualidade de vida com redução da sudorese em pacientes com hiperidrose, mas permanece incerto se a aplicação tópica exerce efeitos locais ou sistêmicos. O objetivo principal deste estudo é avaliar o impacto da oxibutinina tópica na hiperidrose axilar. Vinte pacientes com hiperidrose axilar serão randomizados em três grupos. O Grupo A receberá 2,5 mg de oxibutinina oral com diferentes posologias do primeiro ao 35º dia. O Grupo B receberá um placebo tópico na forma de spray, e o Grupo C receberá um spray de oxibutinina a 10%, com duas borrifadas em cada axila duas vezes ao dia por 35 dias (produto em investigação). O desfecho primário será a avaliação da eficácia do spray tópico de oxibutinina, avaliada pelo número de pacientes que apresentam melhora na gravidade da condição. O estudo TODAY mostrará evidências sobre os efeitos da oxibutinina tópica, avaliando seu impacto na hiperidrose axilar.